Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 134000
                    [Title] => Study centers in 40 countries involved in heart pr
                    [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.


                    [DatePublished] => 2001-09-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 83550
                    [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
                    [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.


The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.


                    [DatePublished] => 2001-06-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ONTARGET

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 134000
                    [Title] => Study centers in 40 countries involved in heart pr
                    [Summary] => A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular protection trial.


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced this at the European Society of Cardiology Congress in Stockholm, Sweden.


                    [DatePublished] => 2001-09-17 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 83550
                    [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
                    [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.


The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.


                    [DatePublished] => 2001-06-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Study centers in 40 countries involved in heart pr

September 17, 2001 - 12:00am

A total of 793 study centers in 40 countries have been recruited to enroll 28,400 patients over two years for the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) cardiovascular...

Science and Environment

Boehringer Ingelheim sets largest cardiovascular protection trial

June 18, 2001 - 12:00am

MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors. The study, announced...

Science and Environment